Closing Time: The 18-Day Oxycodone Refill With Three Prescribers
A 34-year-old patient walks into a community pharmacy in Aurora at 8:40 p.m. with a paper prescription for oxycodone 30 mg, #120, one tablet every 6 hours as needed, written three days earlier by a prescriber 55 miles away. The patient asks to pay cash and wants the brand product. A technician has already typed and filled it. The pharmacist's PDMP review shows oxycodone 30 mg #120 from two different prescribers in the past 90 days, with the most recent #120 filled 18 days ago at a pharmacy across town; alprazolam 2 mg #60 filled 21 days ago from a third prescriber; little other activity. The patient says the other store was out of stock, that the new prescriber has all the records, and that the alprazolam is for flights. The pharmacy closes in 20 minutes, the drive-thru line is six cars deep, and the technician asks whether to just ring it up.
1. Is a PDMP query required here, and what must the pharmacist resolve before either dispensing or refusing?
Read the worked answer
Yes, and the query creates questions rather than closing them. Colorado requires a dispenser to check the PDMP before dispensing a second fill of an opioid or a benzodiazepine, and at least every six months thereafter while therapy continues. This is not a first fill, so the check is mandatory before the bottle leaves the counter.
What the report actually shows:
- Two opioid prescribers in 90 days with no indication either knows about the other.
- An early refill: #120 at four tablets daily is a 30-day supply filled 18 days ago, so the patient is roughly 12 days early.
- Cumulative dose: oxycodone 30 mg x 1.5 = 45 MME per tablet, four tablets daily = 180 MME/day, well above the 90 MME threshold where most guidance expects added safeguards.
- Concurrent benzodiazepine from an unrelated prescriber, which adds respiratory-depression risk on top of an already high opioid dose.
Before deciding, the pharmacist should verify the prescription directly with the issuing office: prescriber identity and DEA number, diagnosis and functional goals, awareness of the other opioid and the alprazolam, and whether a treatment agreement or urine testing exists. Ask the patient plainly and without accusation about the other prescriber and pharmacy. Document each call, who was reached, and the time. A completed PDMP query satisfies a checkbox; it does not by itself discharge the corresponding-responsibility duty under 21 CFR 1306.04(a) and Colorado's parallel provisions.
2. If the pharmacist concludes the red flags cannot be resolved, may the prescription be refused? What must happen to the paper and to the patient?
Read the worked answer
Yes. No pharmacist is compelled to fill a prescription he or she believes was not issued for a legitimate medical purpose, and a refusal grounded in the prescription's objective red flags is a professional judgment, not abandonment or discrimination. The refusal must rest on the findings, never on the patient's appearance, race, disability, or history.
Practical steps:
- Return the original paper prescription unless forgery is suspected. If it is suspected, do not return it; contact the prescriber and handle it as a suspected forgery with law enforcement and the Board as appropriate.
- Tell the patient briefly and neutrally that the pharmacist cannot fill this one today, without lecturing or accusing.
- Offer to call the prescriber with the patient present, and notify the prescriber yourself that the prescription was not filled.
- Offer naloxone, which Colorado pharmacists may dispense without a prescription, and provide referral information for pain and substance use treatment.
- Document objective facts only: what was reviewed, what was said by whom, and the disposition.
A partial fill is not a fix here. A pharmacist may dispense less than the quantity prescribed, but that mechanism addresses quantity or supply problems, not a 12-day-early duplicate opioid. More importantly, at the prescribed rate the patient still has about 12 days of medication, so a refusal creates no abrupt physical gap and no withdrawal emergency requiring a bridge supply.
3. The prescriber's office calls back and says, 'He's a good patient, we know about everything, just fill it.' Is that enough? What documentation would make this defensible either way?
Read the worked answer
A verbal assurance shifts the analysis but does not end it. The pharmacist's duty is personal; a prescriber's blessing does not authorize dispensing that the pharmacist still believes lacks a legitimate medical purpose, and it does not by itself resolve the specific red flags that triggered the concern.
The follow-up call should convert a vague assurance into specific answers:
- What is the diagnosis, and how long has the patient been on this dose?
- Is the prescriber aware of the second opioid prescriber and the alprazolam, by name and date?
- What monitoring exists: treatment agreement, urine drug testing, functional goals, pill counts?
- Who is managing the benzodiazepine, and is there a plan to taper or coordinate?
- Why 180 MME/day rather than a lower dose or a different modality?
A chart note that survives scrutiny contains: the date and time of the PDMP query and the specific elements reviewed; each prescriber contacted, the name of the person spoken to, and verbatim substance of the conversation; the rationale for dispensing or refusing; and, if dispensed, the counseling given, the naloxone offer, and any quantity limitation. 'Doctor approved' alone is not a rationale. If the prescriber cannot answer the concrete questions, or confirms facts that contradict the patient's account, refusal and prescriber notification are the defensible course.